Dr. Adi Diab on Baseline Tumor Immune Signatures and Therapy Response in Solid Tumors
June 20th 2019Cancer Network spoke with Adi Diab, MD, of MD Anderson Cancer Center, on the link between baseline tumor immune signatures and response to bempegaldesleukin and nivolumab in patients with advanced solid tumors.